Randomized Study of Docetaxel Versus Docetaxel Plus Genasense (G3139; Bcl-2 Antisense Oligonucleotide) [oblimersen] in Patients With Previously Treated Non-Small Cell Lung Cancer

Trial Profile

Randomized Study of Docetaxel Versus Docetaxel Plus Genasense (G3139; Bcl-2 Antisense Oligonucleotide) [oblimersen] in Patients With Previously Treated Non-Small Cell Lung Cancer

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 14 Apr 2009

At a glance

  • Drugs Docetaxel; Oblimersen
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top